A group of Tennessee healthcare defendants in a federal multidistrict litigation say that plaintiffs and defendants have disparate access to the discovery produced in the bankruptcy case of a compounding pharmacy that made steroids tainted with fungus and that led to an outbreak of fungal meningitis.
Saint Thomas West Hospital and affiliated defendants are defending claims they harmed their patients by administering those steroids tainted with fungus. Without access to that information, Saint Thomas and the other defendants said they can’t prepare a defense on the grounds of comparative fault, indemnity or contribution.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
